INTEGRATED DIAGNOSTICS HOLDINGS PLC Financials Integrated Diagnostics Holdings plc
Equities
IDHC
JE00BLKGSR75
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3055 USD | +0.16% |
|
+7.38% | -13.94% |
| Jun. 27 | Integrated Diagnostics Holdings Amends Egyptian Exchange Delisting Buyback Price | MT |
| Jun. 03 | Transcript : Integrated Diagnostics Holdings plc, Q1 2024 Earnings Call, Jun 03, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,600 | 10,355 | 771 | 9,392 | 213 | 8,798 | - | - |
| Enterprise Value (EV) 1 | 9,076 | 9,572 | -712.8 | 9,392 | 571.1 | 8,794 | 8,149 | 7,606 |
| P/E ratio | 18.8 x | 17.4 x | 0.55 x | 17.4 x | 0.42 x | 9.16 x | 8.27 x | 6.28 x |
| Yield | - | 4.45% | 169% | - | - | 4.37% | 10.2% | 13.5% |
| Capitalization / Revenue | 4.31 x | 3.9 x | 0.15 x | 2.61 x | 0.05 x | 1.68 x | 1.35 x | 1.14 x |
| EV / Revenue | 4.08 x | 3.6 x | -0.14 x | 2.61 x | 0.14 x | 1.68 x | 1.25 x | 0.98 x |
| EV / EBITDA | 9.61 x | 8.17 x | -0.28 x | 8.02 x | 0.48 x | 5.83 x | 3.92 x | 2.86 x |
| EV / FCF | 18.7 x | 12.5 x | -0.3 x | - | - | 69.8 x | 9.97 x | 6.83 x |
| FCF Yield | 5.33% | 7.98% | -335% | - | - | 1.43% | 10% | 14.6% |
| Price to Book | 4.33 x | 4.56 x | 0.3 x | - | 0.08 x | 2.66 x | 2.47 x | 2.24 x |
| Nbr of stocks (in thousands) | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | 600,000 | - | - |
| Reference price 2 | 16.00 | 17.26 | 1.285 | 15.65 | 0.3550 | 14.66 | 14.66 | 14.66 |
| Announcement Date | 4/28/20 | 5/19/21 | 4/21/22 | 4/6/23 | 3/28/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,226 | 2,656 | 5,225 | 3,605 | 4,123 | 5,237 | 6,503 | 7,728 |
| EBITDA 1 | 944.3 | 1,171 | 2,530 | 1,172 | 1,192 | 1,509 | 2,079 | 2,659 |
| EBIT 1 | 790.8 | 985.5 | 2,291 | 832.2 | 737.8 | 1,061 | 1,577 | 2,070 |
| Operating Margin | 35.52% | 37.11% | 43.85% | 23.08% | 17.9% | 20.25% | 24.25% | 26.79% |
| Earnings before Tax (EBT) 1 | 758.1 | 969.1 | 2,232 | 853.6 | - | 1,229 | 1,434 | 1,974 |
| Net income 1 | 510.9 | 594 | 1,413 | 541.1 | - | 872 | 974.5 | 1,286 |
| Net margin | 22.95% | 22.37% | 27.04% | 15.01% | - | 16.65% | 14.99% | 16.65% |
| EPS 2 | 0.8525 | 0.9900 | 2.350 | 0.9000 | 0.8500 | 1.601 | 1.773 | 2.334 |
| Free Cash Flow 1 | 484.1 | 764.1 | 2,387 | - | - | 126 | 817 | 1,113 |
| FCF margin | 21.74% | 28.77% | 45.69% | - | - | 2.41% | 12.56% | 14.4% |
| FCF Conversion (EBITDA) | 51.26% | 65.26% | 94.36% | - | - | 8.35% | 39.3% | 41.86% |
| FCF Conversion (Net income) | 94.75% | 128.64% | 168.98% | - | - | 14.45% | 83.84% | 86.51% |
| Dividend per Share 2 | - | 0.7683 | 2.170 | - | - | 0.6404 | 1.499 | 1.975 |
| Announcement Date | 4/28/20 | 5/19/21 | 4/21/22 | 4/6/23 | 3/28/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q1 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,166 | - | 1,706 | - | - | 1,180 | 773.6 | 846.3 | 915.3 |
| EBITDA | 527.9 | - | 803 | - | - | - | - | - | - |
| EBIT 1 | 424.4 | - | - | - | - | 396.4 | 166.1 | 186.4 | 128.8 |
| Operating Margin | 36.41% | - | - | - | - | 33.58% | 21.47% | 22.02% | 14.07% |
| Earnings before Tax (EBT) | - | - | 695.3 | - | - | - | - | - | - |
| Net income | 287.1 | 178.8 | 415.2 | 646.4 | 766.2 | 296.6 | 124.9 | -18.19 | - |
| Net margin | 24.63% | - | 24.34% | - | - | 25.13% | 16.15% | -2.15% | - |
| EPS | 0.4800 | 0.2975 | - | 1.080 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/28/20 | 9/2/20 | 5/19/21 | 9/2/21 | 4/21/22 | 6/8/22 | 9/12/22 | 11/17/22 | 6/1/23 |
1EGP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 358 | - | - | - |
| Net Cash position 1 | 524 | 784 | 1,484 | - | - | 3.56 | 649 | 1,192 |
| Leverage (Debt/EBITDA) | - | - | - | - | 0.3004 x | - | - | - |
| Free Cash Flow 1 | 484 | 764 | 2,387 | - | - | 126 | 817 | 1,113 |
| ROE (net income / shareholders' equity) | 22.8% | 26.5% | 58.2% | - | 21.1% | 28% | 31.3% | 37.5% |
| ROA (Net income/ Total Assets) | 14.2% | 15% | 27.1% | - | - | - | - | - |
| Assets 1 | 3,595 | 3,966 | 5,207 | - | - | - | - | - |
| Book Value Per Share 2 | 3.690 | 3.780 | 4.300 | - | 4.460 | 5.510 | 5.930 | 6.540 |
| Cash Flow per Share 2 | 1.160 | 1.470 | 3.780 | - | 0.9100 | 1.430 | 2.480 | 3.340 |
| Capex 1 | 213 | 118 | 253 | - | 323 | 289 | 306 | 324 |
| Capex / Sales | 9.58% | 4.46% | 4.85% | - | 7.85% | 5.52% | 4.7% | 4.19% |
| Announcement Date | 4/28/20 | 5/19/21 | 4/21/22 | 4/6/23 | 3/28/24 | - | - | - |
1EGP in Million2EGP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.66
EGP
Average target price
27.26
EGP
Spread / Average Target
+85.94%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.94% | 183M | |
| +19.84% | 84.94B | |
| -25.24% | 74.07B | |
| -1.34% | 26.15B | |
| +4.56% | 18.03B | |
| -9.29% | 17.38B | |
| +4.52% | 16.01B | |
| +78.16% | 13.7B | |
| +77.84% | 13.13B | |
| -26.14% | 12.74B |
- Stock Market
- Equities
- IDHC Stock
- Financials Integrated Diagnostics Holdings plc
